Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Insomnia Med Quviviq Now Available in Japan: Nxera/Shionogi
December 20, 2024
- PeptiDream Gets Milestone from Novartis on PI Launch
December 20, 2024
- GSK Applauds Japan’s Plan to Include Shingles Vaccines in NIP
December 19, 2024
- Sumitomo Plots 350 Billion Yen Cell Therapy Biz in Late 2030s
December 18, 2024
- Sumitomo Group to Launch Regenerative/Cell Therapy Joint Venture
December 18, 2024
- Chugai Touts 9 Late-Stage Oncology Assets for 23 Indications, Hails Deregulations
December 18, 2024
- Daiichi Sankyo Puts Up 600 Billion Yen to Bolster ADC Supply Regime
December 18, 2024
- Takeda, Tohoku University Form Strategic Alliance to Expedite Drug R&D
December 18, 2024
- Jazz’s Epilepsy Drug Candidate Nearing Submission as Japan Lifts Ban on Cannabis-Derived Meds
December 18, 2024
- ASKA Begins Japan PIII for Relugolix Combo Drug
December 17, 2024
- Kyorin Licenses Novel OSA Treatment from Bayer
December 17, 2024
- Strattera and All Generic Versions Now under Supply Restrictions in Japan
December 17, 2024
- COVID Jab Kostaive Gets EMA Backing: Meiji
December 17, 2024
- Mochida Ties Up with Kuhnil to Market Epadel in South Korea
December 17, 2024
- Takeda Sees Up to US$20 Billion Sales Potential with 6 Late-Stage Assets
December 16, 2024
- Teijin Seek Japan Approval for Ascendis’ Hypoparathyroidism Drug
December 16, 2024
- Amgen Japan Marks “Significant Milestone” with Tepezza Release, Eyes More Launches
December 16, 2024
- BMS Files Augtyro for NTRK-Positive Solid Tumors in Japan
December 16, 2024
- EA Pharma Bags Japan, Asia Rights to Newron’s Schizophrenia Drug
December 16, 2024
- Mitsubishi Tanabe to Reinstate CEO Role, with Tsujimura at Its Helm
December 16, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…